Correlation Between Mineralys Therapeutics, and Fennec Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Mineralys Therapeutics, and Fennec Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mineralys Therapeutics, and Fennec Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Mineralys Therapeutics, Common and Fennec Pharmaceuticals, you can compare the effects of market volatilities on Mineralys Therapeutics, and Fennec Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mineralys Therapeutics, with a short position of Fennec Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mineralys Therapeutics, and Fennec Pharmaceuticals.

Diversification Opportunities for Mineralys Therapeutics, and Fennec Pharmaceuticals

-0.38

Correlation Coefficient

Mineralys Therapeutics,  Fennec Pharmaceuticals

Very good diversification

The 3 months correlation between Mineralys and Fennec is -0.38. Overlapping area represents the amount of risk that can be diversified away by holding Mineralys Therapeutics, Common and Fennec Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Fennec Pharmaceuticals and Mineralys Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mineralys Therapeutics, Common are associated (or correlated) with Fennec Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Fennec Pharmaceuticals has no effect on the direction of Mineralys Therapeutics, i.e., Mineralys Therapeutics, and Fennec Pharmaceuticals go up and down completely randomly.

Pair Corralation between Mineralys Therapeutics, and Fennec Pharmaceuticals

Given the investment horizon of 90 days Mineralys Therapeutics, Common is expected to under-perform the Fennec Pharmaceuticals. In addition to that, Mineralys Therapeutics, is 1.83 times more volatile than Fennec Pharmaceuticals. It trades about -0.12 of its total potential returns per unit of risk. Fennec Pharmaceuticals is currently generating about 0.09 per unit of volatility. If you would invest  624.00  in Fennec Pharmaceuticals on December 1, 2024 and sell it today you would earn a total of  78.00  from holding Fennec Pharmaceuticals or generate 12.5% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Mineralys Therapeutics, Common  vs.  Fennec Pharmaceuticals

Mineralys Therapeutics,

Risk-Adjusted Performance

Very Weak

Over the last 90 days Mineralys Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Fennec Pharmaceuticals

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Fennec Pharmaceuticals are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating basic indicators, Fennec Pharmaceuticals exhibited solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Mineralys Therapeutics, and Fennec Pharmaceuticals

The main advantage of trading using opposite Mineralys Therapeutics, and Fennec Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mineralys Therapeutics, position performs unexpectedly, Fennec Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Fennec Pharmaceuticals will offset losses from the drop in Fennec Pharmaceuticals' long position.

The idea behind Mineralys Therapeutics, Common and Fennec Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.